Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06623201 · ClinicalTrials.gov registry record · Phase 1
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
A Phase 1 study of Basal Cell Carcinoma (BCC), sponsored by Nathalie Zeitouni.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06623201: Recruiting Phase 1 study of Basal Cell Carcinoma (BCC), sponsored by Nathalie Zeitouni.
NCT06623201 is a Phase 1 study of Basal Cell Carcinoma (BCC) that is actively recruiting participants, run by Nathalie Zeitouni. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06623201, a Phase 1 study of Basal Cell Carcinoma (BCC), is actively recruiting participants, sponsored by Nathalie Zeitouni.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions. Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatment can cause scarring. Photodynamic therapy uses light along with a drug applied to the skin to kill the cancer cells and cause them to break apart. The light used can cause the skin to feel warm, but does not cause scarring.
Primary Outcome
Primary efficacy outcome measure: the overall response rate (ORR) to the combination therapy in patients, which is the proportion of evaluable study subjects who has complete response (CR) or partial response (PR) to the study treatment as defined in the protocol.
Conditions Studied
Interventions
- DRUG aminolevulinic acid HCL (ALA)
- DEVICE BLU-U device model 4170E
Study Locations (1)
Arizona
- Medical Dermatology Specialists - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
What NCT06623201 shows while recruiting
NCT06623201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Basal Cell Carcinoma (BCC) appearing as the primary indexed condition, and to 2 interventions - of which aminolevulinic acid HCL (ALA) is the first listed.
NCT06623201 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06623201 about?
NCT06623201 is a clinical study titled "Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas". This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions. Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatme...
What is the current status of trial NCT06623201?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-10-07. Estimated completion is 2026-12-01.
What conditions does trial NCT06623201 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma (BCC).
What interventions are being tested in trial NCT06623201?
The interventions under investigation include: aminolevulinic acid HCL (ALA) (DRUG), BLU-U device model 4170E (DEVICE).
Who is sponsoring clinical trial NCT06623201?
This trial is sponsored by Nathalie Zeitouni, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06623201 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma (BCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06623201's enrollment target sits among peer trials
20 1630th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI